Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

NCT04461600 is registered in ClinicalTrials.gov with Ayala Pharmaceuticals, Inc, as lead sponsor.

NCT NCT04461600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04461600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
Lead sponsor
Ayala Pharmaceuticals, Inc,
Phase
Phase 2
Overall status
Terminated
Start date
August 14, 2020
Completion date
October 11, 2022
Enrollment
18 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer